Price History
Feb 9, 2026 — Aug 28, 2026Investment Snapshot
- P/E of 51.9 — elevated valuation multiple
- Piotroski F-Score 4/9 — moderate financial health
- Strong ROE of 114.3% with 33.7% net margin
OMEROS CORP (OMER) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $672 million . Key value metrics: P/E ratio 51.9, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
OMEROS CORP — Fundamental Analysis Summary
OMEROS CORP (OMER) trades at a trailing P/E of 51.9x — 108% above the Healthcare sector average of 25.0x.
On financial health, OMER shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 114.3% (sector average: -20.4%).
StockPik's composite Value Score for OMER is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
OMER reports a high gross margin of 96.4% (sector average: 36.6%) and a negative operating margin of -198.0%.
OMER shows earnings growing at 98%.